Physician profile
Gregory Bell
NPI 1083689939
$1,826.18
in general payments reported to CMS, 2019-2025
12 companies · $92.69 in 2025
The $92.69 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $81.73 · 2021: $18.82 · 2022: $372 · 2023: $403 · 2024: $459 · 2025: $92.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.84 |
| Education | $247.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $558.88 | 2019-2025 | |
| Janssen Biotech, INC. | $374.63 | 2022-2024 | Tremfya |
| Amgen INC. | $195.86 | 2020-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $166.38 | 2019-2025 | Rinvoq |
| Celgene Corporation | $166.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $93.33 | 2022-2024 | |
| Lilly USA, LLC | $69.09 | 2019-2024 | Taltz |
| Genentech USA, INC. | $64.09 | 2019-2024 | Actemra |
| Alexion Pharmaceuticals, INC. | $49.12 | 2023-2025 | Strensiq |
| Astrazeneca Pharmaceuticals Lp | $34.69 | 2022-2025 | |
| Glaxosmithkline, LLC. | $32.69 | 2022-2024 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $21.08 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.